A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing
    • Primary and study completion moved earlier from Oct 2027 to Jul 2027
    • Site details revised at 21 of 21 sites
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Site contacts updated at 1 of 21 sitesv3
  4. Recruitment opened
    • Start date changed from estimate of Mar 2026 to Feb 27, 2026
    • Site details revised at 21 of 21 sites
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
Diabetes
5,141 trials monitored
See 246 trials at risk
Obesity
3,909 trials monitored
See 165 trials at risk
Type 2 Diabetes
2,257 trials monitored
See 120 trials at risk
The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.
Trial Details
NCT Number NCT07438444
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2, Obesity, Overweight
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 344 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov